Entrada Therapeutics Short - 8 Jul 2022Entrada Therapeutics Short
Entry: 10.90
Take profit: 6.53
Stop loss: 13.07
Risk/reward: 2.01
Next report date
Report period
Q1 2024
EPS estimate
−0.59USD
Revenue estimate
14.98 MUSD
−0.21USD
−6.69 MUSD
129.01 MUSD
18.02 M
About Entrada Therapeutics, Inc.
Sector
Industry
CEO
Dipal Doshi
Website
Headquarters
Boston
Employees (FY)
159
Founded
2016
FIGI
BBG00MTSMC16
Entrada Therapeutics, Inc. operates as a biotechnology company. It focuses on delivery of biomolecules into the cell to treat devastating diseases. The firm offers intracellular enzyme replacement therapy and protein-protein interaction inhibitors programs. The company focuses on creating and expanding pipeline of oligonucleotide, antibody, enzyme, protein and peptide programs to target and engage underlying drivers of diseases. Entrada Therapeutics was founded by Dehua Pei in September 22, 2016 and is headquartered in Boston, MA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of TRDA is 12.45 USD — it has increased by 0.73% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Entrada Therapeutics, Inc. stocks are traded under the ticker TRDA.
Entrada Therapeutics, Inc. is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
TRDA stock is 5.21% volatile and has beta coefficient of 0.90. Check out the list of the most volatile stocks — is Entrada Therapeutics, Inc. there?
TRDA earnings for the last quarter are 1.02 USD per share, whereas the estimation was −0.74 USD resulting in a 238.78% surprise. The estimated earnings for the next quarter are −0.17 USD per share. See more details about Entrada Therapeutics, Inc. earnings.
Entrada Therapeutics, Inc. revenue for the last quarter amounts to 43.74 M USD despite the estimated figure of 9.60 M USD. In the next quarter revenue is expected to reach 23.69 M USD.
Yes, you can track Entrada Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
TRDA stock has risen by 5.24% compared to the previous week, the month change is a 11.01% fall, over the last year Entrada Therapeutics, Inc. has showed a 9.88% decrease.
TRDA net income for the last quarter is −9.54 M USD, while the quarter before that showed 35.46 M USD of net income which accounts for −126.91% change. Track more Entrada Therapeutics, Inc. financial stats to get the full picture.
Today Entrada Therapeutics, Inc. has the market capitalization of 419.29 M, it has increased by 2.99% over the last week.
No, TRDA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, TRDA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Entrada Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 27, 2024, the company has 159.00 employees. See our rating of the largest employees — is Entrada Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Entrada Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Entrada Therapeutics, Inc. stock shows the strong sell signal. See more of Entrada Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Entrada Therapeutics, Inc. future price: according to them, TRDA price has a max estimate of 22.00 USD and a min estimate of 20.00 USD. Read a more detailed Entrada Therapeutics, Inc. forecast: see what analysts think of Entrada Therapeutics, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Entrada Therapeutics, Inc. EBITDA is −385.00 K USD, and current EBITDA margin is −0.25%. See more stats in Entrada Therapeutics, Inc. financial statements.